Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1B-cell Malignancies 1

Interventions

Rituximab 6venetoclax 5Bendamustine Hydrochloride 5obinutuzumab 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2idelalisib 2ibrutinib 2Chlorambucil 2umbralisib 1ublituximab 1ofatumumab 1fludarabine phosphate 1duvelisib 1atezolizumab 1Pharmacogenomic Testing 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Lymphocytic, Chronic, B-Cell × zanubrutinib × Clear all
NCT03336333 2026-03-09

SEQUOIA

BeOne Medicines

Phase 3 Active not recruiting
590 enrolled 12 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03734016 2025-03-30

ALPINE

BeiGene

Phase 3 Completed
652 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡